# Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.

> **NCT05305573** · PHASE2 · COMPLETED · sponsor: **Hipra Scientific, S.L.U** · enrollment: 26 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Acute Respiratory Disease

## Interventions

- **BIOLOGICAL:** COVID-19 Vaccine HIPRA 40 ug/dose
- **BIOLOGICAL:** Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection

## Key facts

- **NCT ID:** NCT05305573
- **Lead sponsor:** Hipra Scientific, S.L.U
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-25
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05305573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05305573, "Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05305573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*